从投资策略上看，继续关注华为链整车及汽零，2025 年具备竞争力的自主品牌及在智驾 技术方面领先的新势力企业将继续扩大市场份额；预计部分央国企通过自身改革及加强 对外合作等，实现困境反转。建议持续关注部分汽车行业央国企及人形机器人链、华为 产业链、小米产业链、T 链、智驾产业链公司。 尊界 S800 即将发布，继续关注华为链及机 器人产业链公司 ——汽车行业周报（0519-0525） 核心观点 投资建议与投资标的 风险提示 宏观经济下行影响汽车需求、上游原材料价格波动影响、车企价格战压力。 建议关注：上汽集团、江淮汽车、比亚迪、长安汽车、中国重汽、广汽集团、宇通客 车；新泉股份、银轮股份、岱美股份、拓普集团、嵘泰股份、经纬恒润、爱柯迪、保隆 科技、精锻科技、贝斯特、瑞鹄模具、上声电子、双林股份、华阳集团、华域汽车、伯 特利、德赛西威、科博达、星宇股份、三花智控、继峰股份、上海沿浦、福耀玻璃、浙 江荣泰等。 汽车与零部件行业 行业研究 | 行业周报 国家/地区 中国 行业 汽车与零部件行业 报告发布日期 2025 年 05 月 26 日 中性（维持） | 姜雪晴 | jiangxueqing@orientsec ...

固定收益 | 动态跟踪 徐沛翔 xupeixiang@orientsec.com.cn 存单利率重回下行时间点或早于预期 固定收益市场周观察 研究结论 风险提示 政策变化超预期；货币政策变化超预期；经济基本面变化超预期；信用风险暴露超预 期；数据统计可能存在遗误 报告发布日期 2025 年 05 月 26 日 | 齐晟 | qisheng@orientsec.com.cn | | --- | --- | | | 执业证书编号：S0860521120001 | | 杜林 | dulin@orientsec.com.cn | | | 执业证书编号：S0860522080004 | | 王静颖 | wangjingying@orientsec.com.cn | | | 执业证书编号：S0860523080003 | | 降准是对债市行情的确认还是催化？ | 2025-05-22 | | --- | --- | | 如何看待未来资金面：固定收益市场周观 | 2025-05-19 | | 察 | | | 短期可适当做陡曲线，长端以震荡思路对 | 2025-05-12 | | 待：固定收益市场周观察 | | 有关分析师的 ...

建议关注：上汽集团、江淮汽车、比亚迪、长安汽车、中国重汽、广汽集团、宇通客 车；新泉股份、银轮股份、岱美股份、拓普集团、嵘泰股份、经纬恒润、爱柯迪、保隆 科技、精锻科技、贝斯特、瑞鹄模具、上声电子、双林股份、华阳集团、华域汽车、伯 特利、德赛西威、科博达、星宇股份、三花智控、继峰股份、上海沿浦、福耀玻璃、浙 江荣泰等。 尊界 S800 即将发布，继续关注华为链及机 器人产业链公司 ——汽车行业周报（0519-0525） 核心观点 投资建议与投资标的 从投资策略上看，继续关注华为链整车及汽零，2025 年具备竞争力的自主品牌及在智驾 技术方面领先的新势力企业将继续扩大市场份额；预计部分央国企通过自身改革及加强 对外合作等，实现困境反转。建议持续关注部分汽车行业央国企及人形机器人链、华为 产业链、小米产业链、T 链、智驾产业链公司。 风险提示 宏观经济下行影响汽车需求、上游原材料价格波动影响、车企价格战压力。 汽车与零部件行业 行业研究 | 行业周报 国家/地区 中国 行业 汽车与零部件行业 报告发布日期 2025 年 05 月 26 日 中性（维持） | 姜雪晴 | jiangxueqing@orientsec ...

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 42.24 CNY based on a reasonable valuation level of 24 times the earnings per share for 2025 [2][5]. Core Views - The company is entering a harvest period for innovative drugs, although its main business faces short-term pressure due to the impact of centralized procurement on the infusion and generic drug segments [1]. - The company achieved a revenue of 21.81 billion CNY in 2024, reflecting a growth of 1.67%, and a net profit attributable to the parent company of 2.94 billion CNY, up 19.53% [9]. - The first quarter of 2025 saw a revenue decline to 4.39 billion CNY, down 29.42%, and a net profit of 584 million CNY, down 43.07%, primarily due to high base effects from the previous year [9]. - The ADC platform is expected to yield significant commercial results, with key products like SKB264 receiving regulatory approval for multiple indications [9]. - The antibiotic supply-demand structure remains stable, with synthetic biology products contributing to revenue growth [9]. Financial Summary - The company’s projected financials indicate a revenue increase from 21.45 billion CNY in 2023 to 29.19 billion CNY by 2027, with a compound annual growth rate of approximately 13% [4]. - The net profit attributable to the parent company is expected to grow from 2.46 billion CNY in 2023 to 3.62 billion CNY in 2027, with a notable increase in 2024 [4]. - Earnings per share are projected to be 1.76 CNY in 2025, with a gradual increase to 2.27 CNY by 2027 [4][2]. - The gross margin is expected to stabilize around 50% to 52.7% over the forecast period, indicating a solid profitability outlook [4].

投资策略 | 定期报告 进入政策观察期 ——策略周报 0525 研究结论 风险提示 | 张书铭 | 021-63325888*5152 | | --- | --- | | 17 | zhangshuming@orientsec.com.cn | | | 执业证书编号：S0860517080001 | | 张志鹏 | zhangzhipeng@orientsec.com.cn | | | 执业证书编号：S0860522020002 | | 关税降级提振市场风险偏好：——策略周 | 2025-05-19 | | --- | --- | | 报 0518 | | | 逆周期政策提振市场信心：——策略周报 | 2025-05-12 | | 0512 | | | 物来顺应：——策略周报 0505 | 2025-05-06 | | 以稳为主：——策略周报 0428 | 2025-04-28 | | 缺乏稳定一致预期：——策略周报 0421 | 2025-04-20 | 有关分析师的申明，见本报告最后部分。其他重要信息披露见分析师申明之后部分，或请与您的投资代表联系。并请阅读本证券研究报告最后一页的免责申明。 报告发布日期 ...

4 月电新出口整体企稳 核心观点 ⚫ 4 月电新出口整体企稳，逆变器、变压器和电表均呈现环比增长态势，风机出口同 比维系呈现高速增长。 组件：4 月出口 161.58 亿元，环比-1.07%，同比-20.33%。1-4 月累计出口 607.50 亿元，累计同比-28.29%。 逆变器：4 月出口 58.17 亿元，环比+28.17%，同比+17.95%。1-4 月累计出口 180.19 亿元，累计同比+9.94%。 变压器：4 月出口 47.77 亿元，环比+9.27%，同比+33.86%。1-4 月累计出口 178.29 亿元，累计同比+38.30%。 电表：4 月出口 9.80 亿元，环比+28%，同比+34%。1-4 月累计出口 35.32 亿元， 累计同比+14.82%。 风机：4 月出口 1.34 亿美元，环比-7.84%，同比+49.31%。1-4 月累计出口 4.43 亿美元，累计同比+43.84%。 投资建议与投资标的 ⚫ 建议关注德业股份(605117，买入)、阳光电源(300274，未评级)、禾迈股份 (688032，买入)、三星医疗(601567，未评级)、海兴电力(603556，未评级 ...

Investment Rating - The report assigns a "Buy" rating for the company for the first time [1] Core Views - The company is a global leader in ADC and XDC CRDMO, benefiting from strong growth in the ADC sector and unique competitive advantages as an industry leader [5][20] - The ADC market is expected to grow significantly, with projections indicating a market size of $64.7 billion by 2030, driven by advancements in treatment strategies and new drug approvals [9][43] - The company is developing a comprehensive one-stop service platform that covers the entire process from discovery to GMP production, which is expected to accelerate project timelines and enhance growth potential [9][20] Financial Summary - The company’s revenue and net profit have shown rapid growth, with a CAGR of 180% and 121% from 2020 to 2023, respectively [20] - Revenue projections for 2025-2027 are estimated at HKD 5,470.58 million, HKD 7,169.95 million, and HKD 9,202.70 million, with corresponding net profits of HKD 1,257.14 million, HKD 1,695.86 million, and HKD 2,302.43 million [8][6] - The company’s gross margin is expected to improve from 26.35% in 2023 to 34.00% by 2027, while net margin is projected to rise from 13.35% to 25.02% over the same period [8] Market Position - The company holds a 9.8% global market share in the ADC sector, ranking second globally and first domestically, with a significant increase in overseas revenue contribution [68] - The ADC outsourcing service market is projected to grow from $1.5 billion in 2022 to over $11 billion by 2030, indicating a strong demand for the company's services [64][68]

Investment Rating - The report assigns a "Buy" rating for the company for the first time [1]. Core Views - The company is a global leader in ADC and XDC CRDMO, with a market share of 9.8% globally and ranked second worldwide, benefiting from the technological and capacity advantages of its major shareholders [5][68]. - The ADC market is experiencing rapid growth, with a projected CAGR of 30.7% from 2024 to 2030, driven by the increasing adoption of ADCs in cancer treatment [9][43]. - The company is expected to see significant revenue and profit growth, with a forecasted revenue of HKD 5,470.58 million in 2025, representing a 35% year-on-year increase [8]. Financial Forecast and Investment Recommendations - The company is projected to achieve earnings per share of HKD 1.05, HKD 1.41, and HKD 1.91 for the years 2025, 2026, and 2027 respectively, indicating strong growth potential [6]. - The target price is set at HKD 47.81, based on DCF valuation, reflecting the company's leadership position in the ADC CRDMO sector and its robust project pipeline [6]. Company Overview - The company was established in 2013 and went public in 2023, focusing on the development and manufacturing of ADCs and XDCs [14]. - The core management team has extensive experience in the biopharmaceutical industry, enhancing the company's operational capabilities [18]. Revenue Growth and Profitability - The company has experienced a CAGR of 180% in revenue and 121% in net profit from 2020 to 2023, with a projected revenue growth of 91% and net profit growth of 277% in 2024 [20]. - The gross margin and net margin are expected to improve significantly due to enhanced operational efficiency and increased capacity utilization [23]. Market Dynamics - The ADC market is projected to reach USD 6.47 billion by 2030, with a significant shift towards frontline treatments and combination therapies with immunotherapy [43][48]. - The demand for ADC outsourcing services is expected to grow, with the global ADC outsourcing market projected to exceed USD 11 billion by 2030 [64].

金融工程 | 动态跟踪 分红对期指的影响 20250523 研究结论 | | 收盘价 | 分红点数 | 实际价差 | 含分红价差 | | --- | --- | --- | --- | --- | | IH2506 | 2693.00 | 17.28 | -18.85 | -1.58 | | IH2507 | 2664.80 | 54.43 | -47.05 | 7.38 | | IH2509 | 2655.60 | 58.77 | -56.25 | 2.52 | | IH2512 | 2653.80 | 58.77 | -58.05 | 0.72 | 沪深 300 股指期货: | | 收盘价 | 分红点数 | 实际价差 | 含分红价差 | | --- | --- | --- | --- | --- | | IF2506 | 3846.20 | 20.75 | -36.07 | -15.32 | | IF2507 | 3808.80 | 55.62 | -73.47 | -17.86 | | IF2509 | 3777.80 | 66.11 | -104.47 | -38.37 | | IF2512 | 37 ...

Investment Rating - The report maintains a "Buy" rating for Anhui Heli, with a target price of 17.21 CNY [5][2] Core Views - The company faces high costs that are squeezing some profits, but its internationalization and industrial chain layout continue to inject development momentum [1] - Revenue for 2024 is projected to be 17.33 billion CNY, a slight increase of 1% year-on-year, while net profit is expected to be 1.32 billion CNY, reflecting a minimal growth of 0.2% [10] - The company is expanding its overseas strategy, with significant growth in exports and overseas revenue, which accounted for 40% of total revenue in 2024 [10] - The company is enhancing its industrial chain layout by investing in smart logistics and reducing related transactions through acquisitions [10] Financial Summary - Revenue and profit figures for 2023 and projections for 2024-2027 are as follows: - 2023 Revenue: 17.156 billion CNY, 2024 Revenue: 17.325 billion CNY (1% growth) - 2024 Net Profit: 1.32 billion CNY, 2025 Net Profit: 1.442 billion CNY (9.3% growth) [4][10] - The gross margin for 2024 is expected to be 23.46%, an increase of 2.84 percentage points year-on-year [10] - The company’s net profit margin for 2024 is projected at 7.6% [4][10] - The company’s earnings per share (EPS) for 2024 is estimated at 1.48 CNY, with a gradual increase to 2.02 CNY by 2027 [4][10]